B
Bull
Bull · 25%PBM
$4.72
Precio del escenario
$4.370
+0.030 (+0.69%)Al cierre
Loading chart…
- High
- 4.370
- Open
- 4.300
- VWAP
- 4.32
- Vol
- 17.59K
- Mkt Cap
- —
- Low
- 4.210
- Amount
- 75.93K
- EV/EBITDA, TTM
- 0.00
Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.
AI analysis of Psyence Biomedical Ltd (PBM)
holdPsyence Biomedical Ltd is currently priced at $4.57, which is relatively stable but shows a 2.41% increase recently. However, the company reported a significant net loss of $753,254 in Q2 2026, indicating financial challenges. The RSI is at 58.53, suggesting the stock is neither overbought nor oversold, but the forward P/E ratio is at 0, indicating uncertainty in future earnings. While there are positive catalysts such as U.S. government support for ibogaine development, the financial performance raises concerns, making it a hold rather than a buy.
Métricas de valoración
The current forward P/E ratio for Psyence Biomedical Ltd (PBM) is 0.00, compared to its 5-year average forward P/E of 0.00.
Alphio AI Price Scenarios for PBM
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
8.508-19NASDAQ.COMPsyence Biomedical Welcomes U.S. Support for Ibogaine Development
8.508-18NewsfilterPsyence BioMed Welcomes Trump's Support for Accelerated Ibogaine Development
8.507-19NewsfilterEli Lilly Acquires AtaiBeckley, Advancing Psychedelic Drug Market
8.507-19CNBCEli Lilly Acquires AtaiBeckley, Signaling Shift in Psychedelic Drug Market
- 7.505-15Newsfilter
Psyence BioMed Advances Psychedelic Research Initiatives in the U.S.
PBM FAQ — answered by Alphio AI
Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Psyence Biomedical Ltd is currently priced at $4.57, which is relatively stable but shows a 2.41% increase recently. However, the company reported a significant net loss of $753,254 in Q2 2026, indicating financial challenges. The RSI is at 58.53, suggesting the stock is neither overbought nor oversold, but the forward P/E ratio is at 0, indicating uncertainty in future earnings. While there are positive catalysts such as U.S. government support for ibogaine development, the financial performance raises concerns, making it a hold rather than a buy.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.